Audit: QRS - sh-Polypeptide-11 for Hair Regrowth
Audit conducted on 26/09/2026 07:40 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 89 |
| Failed | 0 |
| N/A | 5 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | At a glance traces to ER Conclusion (lines 401-407); protocol, time-to-effect, tiers, gates and monitoring trace to ER lines 154-184, 212-242, 258-290, 306-320, 346, 364-384 |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No established target”, “theoretical antagonism”, “without a control group”, “additive only when deficient” carried over verbatim |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | None appear in the QRS |
| 1.6 | The QRS does not introduce new attributions. | 🟢 |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are glossed (intradermally, lichen planopilaris, HbA1c, FGFR inhibitors, trichoscopy) |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Lede frames the ingredient as an add-on to proven treatments, matching the ER Conclusion’s audience framing |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” in the QRS |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Routes stated as “intradermally”, “injection”, “topical” |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Diff against template shows no heading/label changes |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variables present (marker_# and qualitative_item_# expanded to 7 and 5 instances) |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Template diff shows only variable content and the display:none on benefits_medium changed |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | Empty ER tiers (Medium benefit; High/Medium risk) are hidden as required by 12.5 / 13.5; no ER section populating a visible QRS field is empty |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Home topical approach”, “In-office microneedling or laser approach”, “Injectable approach” verbatim from ER lines 309-311 |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | ER sections condensed (explanations stripped from gates, tiers reduced to labels) |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14 |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration is quoted, and it contains a colon |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.9.25 |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-0926-0707 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Opus |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Opus 5.5 |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 09/26/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | “a lab-made copy of a natural human growth protein, sold as an add-on to proven hair-loss treatments” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | ER lines 401, 403, 405 |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | ER lines 283-290 |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 6 ER items present |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | 5-year melanoma window, 50,000/µL platelet threshold, HbA1c >9%, under-18 preserved |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation used |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Not empty; ER lists populations to avoid |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | ER lines 258-281 |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 13 ER interactions present, none duplicated in Contraindications |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved for all drug classes |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation used |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Not empty |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | ER Therapeutic Protocol lines 308-311 |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Home topical, in-office microneedling/laser, injectable |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER has at least three aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Wound healing 12 weeks (ER line 160), hair at least 3-6 months (ER line 346), wrinkles 4 weeks (ER line 176) |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | High (wound healing), then Low tier in ER order |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three aspects available |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_medium hidden |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high and risks_medium hidden |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | ER lines 362-376 |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 7 ER table rows present |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Matches ER line 366 |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | ER lines 378-384 |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 5 present |
Issues 26/09/2026 07:40
Pass rate 100.00%. No issues found.
Issues 26/09/2026 07:37
- 2.7 — Unexpanded specialist acronyms: “DHEA-S” in marker_6_name (line 663), “FGFR inhibitors” (line 559, glossed only as “cancer drugs”) and “JAK inhibitors” (line 560) are left unexplained, while other acronyms on the sheet are expanded.
Fixes 26/09/2026 07:37
- 2.7 — Unexpanded specialist acronyms explained: Glossed FGFR inhibitors as “cancer drugs that block the receptors sh-Polypeptide-11 activates” (ER wording), added “which block immune-signaling enzymes” after the JAK inhibitor example, and changed marker_6_name to “Free testosterone and DHEA-S, an adrenal androgen (women)”.
Issues 26/09/2026 07:34
- 2.7 — Stripped plain-language glosses: ER glosses were dropped, leaving unexplained jargon: “lichen planopilaris” (line 544), “NSAIDs” (line 561) and “TSH” (line 641), which the ER explains as “inflammatory scarring hair loss”, “nonsteroidal anti-inflammatory drugs” and “thyroid-stimulating hormone”.
Fixes 26/09/2026 07:34
- 2.7 — Restored plain-language glosses: Added the ER’s explanations to “lichen planopilaris (inflammatory scarring hair loss)” in Contraindications, “NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen)” in Key Interactions, and “TSH (thyroid-stimulating hormone)” in the Monitoring table.
Issues 26/09/2026 07:31
- 2.7 — Interaction jargon without glosses: The Key Interactions gate (lines 556-557) drops the ER’s plain-language glosses, leaving “5-alpha-reductase inhibitors” and “Anticoagulants and antiplatelets” unexplained, while the FGFR item keeps its “cancer drugs” gloss.
Fixes 26/09/2026 07:31
- 2.7 — Interaction jargon glosses restored: Added the ER’s plain-language glosses to two Key Interactions items: “5-alpha-reductase inhibitors (testosterone-conversion blockers: …)” and “Anticoagulants and antiplatelets (blood thinners: …)”.
Issues 26/09/2026 07:27
- 2.7 — Unexplained PRP and HbA1c abbreviations: The Key Interactions item “Microneedling, fractional laser, low-level light therapy and PRP” (line 567) and the Contraindications item “uncontrolled diabetes (HbA1c above 9%)” (line 546) use abbreviations that are not explained anywhere on the sheet, although the ER supplies plain-language glosses for both (platelet-rich plasma; a three-month blood-sugar average).
Fixes 26/09/2026 07:27
- 2.7 — Unexplained PRP and HbA1c abbreviations: Expanded “PRP” to “PRP (platelet-rich plasma)” in Key Interactions and “HbA1c above 9%” to “HbA1c, a three-month blood-sugar average, above 9%” in Contraindications, using the ER’s own glosses.
Issues 26/09/2026 07:24
- 2.7 — Jargon without plain glosses: “intradermally” (action_3_value, line 469), “trichoscopy” in monitoring_cadence (line 687) and the unexpanded acronym “FGFR inhibitors” (caution_items, line 559) appear without the plain-language explanations the ER provides (“into the skin”, “magnified scalp imaging”, “cancer drugs”).
Fixes 26/09/2026 07:24
- 2.7 — Added plain-language glosses: Changed action_3_value to “5 mL intradermally (into the skin) on a 1 cm grid”, the cadence to “trichoscopy (magnified scalp imaging)”, and the FGFR item to “FGFR inhibitors (cancer drugs: erdafitinib, pemigatinib, futibatinib)”, using the ER’s own explanations.
Issues 26/09/2026 07:23
- 8.4 — Trailing rationale in contraindication: The Contraindications item “Pregnancy or breastfeeding (no safety data)” (line 543) keeps the explanatory parenthetical “(no safety data)”, which is a rationale rather than a preserved threshold, time window, severity or staging qualifier.
Fixes 26/09/2026 07:23
- 8.4 — Trailing rationale in contraindication: Changed the Contraindications item from “Pregnancy or breastfeeding (no safety data)” to “Pregnancy or breastfeeding”, removing the explanatory parenthetical.
Issues 26/09/2026 07:19
- 1.1 / 7.4 — Unscoped “tested alone” claim: At a Glance (line 433) states “no human study with a comparison group has tested it alone”, dropping the ER Conclusion scope “for hair” (“No controlled human study has tested the ingredient alone for hair”).
Fixes 26/09/2026 07:19
- 1.1 / 7.4 — Scoped “tested alone” claim: Changed At a Glance “no human study with a comparison group has tested it alone” to “…has tested it alone for hair”, matching the ER Conclusion; “animal studies with mixed results” condensed to “mixed animal studies” to stay within 70 words.
Issues 26/09/2026 07:18
- 7.5 — Research jargon in lede: Line 433 says “no controlled human study has tested it alone”; “controlled” is a research-design term a non-specialist would not know exactly and should be replaced with plain wording such as “with a comparison group”.
Fixes 26/09/2026 07:18
- 7.5 — Research jargon in lede: Replaced “no controlled human study has tested it alone” with “no human study with a comparison group has tested it alone” in [at_a_glance] (now 70 words).
Issues 26/09/2026 07:13
- 2.13 — Audience framing dropped from lede: at_a_glance (QRS line 433) reduces the ER Conclusion’s “For health-focused adults already using proven hair-loss treatments, it is sold as an add-on” (ER line 401) to “sold as an add-on for thinning hair”, losing the takeaway that it complements rather than replaces proven therapy.
Fixes 26/09/2026 07:13
- 2.13 — Audience framing restored in lede: Changed at_a_glance from “sold as an add-on for thinning hair” to “sold as an add-on to proven hair-loss treatments”, matching the ER Conclusion’s framing (67 words).
Issues 26/09/2026 07:10
- 2.7 — Unexplained FGF jargon in Time to effect: time_1_sub (line 489) reads “with pharmaceutical recombinant acidic FGF”; “FGF” is never expanded in the QRS and “recombinant acidic FGF” is specialist jargon where plain language is available.
Fixes 26/09/2026 07:10
- 2.7 — Plain-language time_1_sub wording: Replaced “with pharmaceutical recombinant acidic FGF” with “with a pharmaceutical version of the protein, not cosmetic sh-Polypeptide-11”, matching the ER statement that both wound trials used pharmaceutical, not cosmetic, material.